Sue Perlman

Idebenone failed to show a significant difference when compared to a placebo in Friedreich's ataxia

posted on May 22, 2009 - 3:01pm
On May 19, 2009, Santhera Pharmaceuticals reported that a phase 3 trial of its idebenone compound Catena showed the drug was not associated with a statistically significant benefit in 70 children between 8 and 17 years old with Friedreich's ataxia who took it for six months. (See the company's press release, Santhera's US Phase III IONIA Trial in Friedreich's Ataxia Misses Primary Endpoint.)

New content is being added every day. Please check back again.